(0.32%) 5 116.17 points
(0.38%) 38 386 points
(0.35%) 15 983 points
(0.11%) $82.72
(1.13%) $2.05
(-0.44%) $2 347.30
(-0.81%) $27.44
(-0.20%) $959.60
(-0.21%) $0.933
(-0.32%) $10.99
(-0.55%) $0.796
(1.56%) $93.31
-0.48% INR 72.65
Live Chart Being Loaded With Signals
Krebs Biochemicals & Industries Limited manufactures and sells active pharmaceutical ingredients in India. The company develops biotech processes for application in medicine, agriculture, and industry fields...
Stats | |
---|---|
Dagens volum | 2 900.00 |
Gjennomsnittsvolum | 14 948.00 |
Markedsverdi | 1.57B |
EPS | INR0 ( 2024-02-11 ) |
Neste inntjeningsdato | ( INR0 ) 2024-05-21 |
Last Dividend | INR2.90 ( 2005-09-14 ) |
Next Dividend | INR0 ( N/A ) |
P/E | -7.64 |
ATR14 | INR0.576 (0.79%) |
Volum Korrelasjon
Krebs Biochemicals & Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Krebs Biochemicals & Korrelasjon - Valuta/Råvare
Krebs Biochemicals & Økonomi
Annual | 2022 |
Omsetning: | INR521.34M |
Bruttogevinst: | INR264.57M (50.75 %) |
EPS: | INR-11.45 |
FY | 2022 |
Omsetning: | INR521.34M |
Bruttogevinst: | INR264.57M (50.75 %) |
EPS: | INR-11.45 |
FY | 2022 |
Omsetning: | INR529.41M |
Bruttogevinst: | INR-207.59M (-39.21 %) |
EPS: | INR-20.74 |
FY | 2021 |
Omsetning: | INR386.06M |
Bruttogevinst: | INR-136.26M (-35.29 %) |
EPS: | INR-14.53 |
Financial Reports:
No articles found.
Krebs Biochemicals & Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
First Dividend | INR2.90 | 2005-09-14 |
Last Dividend | INR2.90 | 2005-09-14 |
Next Dividend | INR0 | N/A |
Payout Date | 2005-10-01 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | INR2.90 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.38 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 3.18 | |
Div. Directional Score | 1.228 | -- |
Year | Amount | Yield |
---|---|---|
2005 | INR0 | 0.00% |
2006 | INR0 | 0.00% |
2007 | INR0 | 0.00% |
2008 | INR0 | 0.00% |
2009 | INR0 | 0.00% |
2010 | INR0 | 0.00% |
2011 | INR0 | 0.00% |
2012 | INR0 | 0.00% |
2013 | INR0 | 0.00% |
2014 | INR0 | 0.00% |
2015 | INR0 | 0.00% |
2016 | INR0 | 0.00% |
2017 | INR0 | 0.00% |
2018 | INR0 | 0.00% |
2019 | INR0 | 0.00% |
2020 | INR0 | 0.00% |
2021 | INR0 | 0.00% |
2022 | INR0 | 0.00% |
2023 | INR0 | 0.00% |
2024 | INR0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SOBHA.NS | Dividend Junior | 2023-07-28 | Annually | 18 | 0.43% | |
MMP.NS | Dividend Junior | 2023-08-18 | Annually | 4 | 0.49% | |
HDFC.NS | Dividend Junior | 2023-05-16 | Annually | 23 | 0.85% | |
BHAGCHEM.NS | Dividend Junior | 2023-07-27 | Annually | 4 | 0.14% | |
RAIN.NS | Dividend Junior | 2023-05-19 | Annually | 18 | 0.39% | |
KIRLOSBROS.NS | Dividend Junior | 2023-07-25 | Annually | 17 | 0.99% | |
EMMBI.NS | Dividend Junior | 2023-08-04 | Annually | 14 | 0.28% | |
AKSHARCHEM.NS | No Dividend Player | 2023-09-20 | Annually | 7 | 0.34% | |
SUPRAJIT.NS | Dividend Junior | 2023-09-18 | Semi-Annually | 20 | 0.45% | |
NBIFIN.NS | Dividend Junior | 2023-08-11 | Sporadic | 8 | 0.01% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.417 | 1.500 | -8.34 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | 0.200 | 1.500 | 8.88 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | -3.69 | 1.000 | -2.48 | -2.48 | [3 - 30] |
operatingCashFlowPerShareTTM | 6.10 | 2.00 | 7.97 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 6.10 | 2.00 | 6.95 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.739 | 1.000 | 1.015 | 1.015 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.329 | 1.000 | -8.57 | -8.57 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | -0.725 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -7.51 | 1.000 | -0.859 | 0 | [1 - 100] |
returnOnEquityTTM | 0.200 | 2.50 | 9.28 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 6.10 | 2.00 | 7.97 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 6.10 | 2.00 | 7.97 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.175 | 1.500 | -2.17 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.263 | 1.000 | 5.91 | 0 | [0.1 - 0.5] |
Total Score | 3.18 |
Krebs Biochemicals &
Krebs Biochemicals & Industries Limited manufactures and sells active pharmaceutical ingredients in India. The company develops biotech processes for application in medicine, agriculture, and industry fields. Its products, such as androstenedione, lovastatin, and simvastatin for anti-cholesterol and steroid intermediate applications. The company is also developing various products, including amlodipine, cetirizine, orlistat, serratiopepetidase, telmisartan, and phenylephrine for anti-hypertension, anti-histamine, anti-obesity, anti-inflammatory, and cold and cough applications. In addition, it offers contract manufacturing services for large pharmaceutical and multinational companies. Krebs Biochemicals & Industries Limited was incorporated in 1991 and is headquartered in Hyderabad, India.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.